A randomized, open-label, controlled, multi-centre pilot study evaluating the efficacy and safety of Tenofovir 300 mg PO in combination with peginterferon alpha-2a subcutaneous 180 micrograms for 48 weeks in patients with HBeAg-positive CHB
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- 03 Nov 2013 Interim results (n=15) presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases.
- 03 Nov 2013 To date 27 patients have been enrolled according to an abstract presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases
- 22 Mar 2011 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.